Concepedia

Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)

Robert A. Figlin, Charles A. Nicolette, Nizar M. Tannir, Scott S. Tykodi, D. Chen, Viraj A. Master, Brian R. Lane, Mark DeBenedette, Tamara Monesmith, Wan Ling Tan,

Annals of Oncology · 2017 · 12 citations · 0 references

DOI

Concepts